NCT03031691View on ClinicalTrials.gov

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

May 31, 2017

Study Completion Date

September 30, 2017

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

brontictuzumab

starting dose of 1.5mg/kg administered intravenously (IV)

DRUG

trifluridine/tipiracil

Trial Locations (5)

Unknown

Denver, Denver

Miami, Miami

Sarasota, Sarasota

Charleston, Charleston

Nashville, Nashville

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY

NCT03031691 - A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter